Conduit Pharmaceuticals files composition of matter patent for AZD5904

Conduit Pharmaceuticals (CDT) announces the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloperoxidase, MPO, inhibitor in the Company’s pipeline. This novel solid form offers significantly enhanced solubility relative to previously studied forms of AZD5904. This improved solubility enables new formulations that were previously not feasible, better aligning the compound’s pharmacokinetics with targeted disease biology and patient needs. The filing represents a significant development for AZD5904, which previously had limited intellectual property coverage restricted to its use in idiopathic male infertility. This composition of matter patent now positions Conduit to potentially secure a new intellectual property runway for the asset of up to 20 years, enabling a renewed strategic focus on broader clinical development opportunities.